

# SSRI Antidepressant Fluoxetine Improving Immunotherapy Efficacy in Advanced Hepatobiliary Malignancy Patients With Depression and Anxiety

NCT07174947

---

<b>Status</b>	RECRUITING
<b>Phase</b>	Phase 2
<b>Sponsor</b>	First Affiliated Hospital of Wenzhou Medical University
<b>Enrollment</b>	240 participants

## Key Eligibility Criteria

---

### Inclusion (11)

- Age: 18 to 80 years old, both male and female are acceptable.
- The histopathological/cytological diagnosis is hepatocellular carcinoma or cholangiocarcinoma. Hepatocellular carcinoma can be diagnosed by imaging.
- Patients with metastatic advanced or locally advanced liver and gallbladder malignancies;
- No treatment has been received and a first-line treatment regimen including PD-1 inhibitors /PD-L1 inhibitors is planned to be carried out;
- Patients with a PHQ-9 score of e10 or a GAD-7 score of e8, that is, those with positive screening for depression or anxiety;
- ... and 6 more (see full listing online)

### Exclusion (10)

- Those with uncorrectable coagulation dysfunction and a distinct bleeding tendency;
- Patients who currently have unstable or active ulcers or gastrointestinal bleeding;
- Severe functional insufficiency of vital organs, such as severe cardiopulmonary insufficiency, etc;
- Patients with hepatic encephalopathy or intractable ascites requiring treatment;
- A history of mental disorders such as bipolar disorder, schizophrenia, and active suicidal ideation;
- ... and 5 more (see full listing online)

## Locations (1 total)

---

First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China